Publikationen von Ashok Kumar Jayavelu
Alle Typen
Zeitschriftenartikel (13)
1.
Zeitschriftenartikel
22 (1), 107 (2023)
Combined proteomics and CRISPR-Cas9 screens in PDX identify ADAM10 as essential for leukemia in vivo. Molecular Cancer 2.
Zeitschriftenartikel
In vivo PDX CRISPR/Cas9 screens reveal mutual therapeutic targets to overcome heterogeneous acquired chemo-resistance. Leukemia (2022)
3.
Zeitschriftenartikel
12, 903691 (2022)
Presence of the GFI1-36N single nucleotide polymorphism enhances the response of MLL-AF9 leukemic cells to CDK4/6 inhibition. Frontiers in Oncology 4.
Zeitschriftenartikel
15, 25 (2022)
Adverse stem cell clones within a single patient's tumor predict clinical outcome in AML patients. Journal of Hematology & Oncology 5.
Zeitschriftenartikel
139 (7), S. 1080 - 1097 (2022)
PLCG1 is required for AML1-ETO leukemia stem cell self-renewal. Blood 6.
Zeitschriftenartikel
36 (2), S. 426 - 437 (2022)
YBX1 mediates translation of oncogenic transcripts to control cell competition in AML. Leukemia 7.
Zeitschriftenartikel
40 (3), S. 301 - 317.e12 (2022)
The proteogenomic subtypes of acute myeloid leukemia. Cancer Cell 8.
Zeitschriftenartikel
131 (21), e151818 (2021)
Signaling defects associated with insulin resistance in nondiabetic and diabetic individuals and modification by sex. Journal of Clinical Investigation 9.
Zeitschriftenartikel
32 (5), S. 844 - 859.e5 (2020)
A Cell-Autonomous Signature of Dysregulated Protein Phosphorylation Underlies Muscle Insulin Resistance in Type 2 Diabetes. Cell Metabolism 10.
Zeitschriftenartikel
588, S. 157 - 163 (2020)
Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. Nature 11.
Zeitschriftenartikel
34 (5), S. 1444 - 1449 (2020)
SHP1 regulates a STAT6-ITGB3 axis in FLT3ITD-positive AML cells. LEUKEMIA 12.
Zeitschriftenartikel
8 (62), S. 105440 - 105457 (2017)
Nuclear membrane-localised NOX4D generates pro-survival ROS in FLT3-ITD-expressing AML. Oncotarget 13.
Zeitschriftenartikel
8 (16), S. 26613 - 26624 (2017)
Synergistic killing of FLT3ITD-positive AML cells by combined inhibition of tyrosine-kinase activity and N-glycosylation. Oncotarget Meeting Abstract (2)
14.
Meeting Abstract
234 (03), S. 183 - 183. GEORG THIEME VERLAG KG, RUDIGERSTR 14, D-70469 STUTTGART, GERMANY (2022)
ADAM10's sheddase function augments the interaction of leukemia cells with the bone marrow niche in PDX models in vivo. In KLINISCHE PADIATRIE, 15.
Meeting Abstract
43 (SUPPL 4), S. 36 - 37. Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020: Abstracts, 09. Oktober 2020 - 11. Oktober 2020. Karger, Basel (2020)
A single nucleotide polymorphism of the transcription factor Growth Factor Independence 1 (GFI1) accelerates AML evolution and sensitizes AML cells to treatment with DNA repair inhibitors. In Oncology Research and Treatment,